For HER2‐positive advanced breast cancer, the preferred first‐line regimen should be dual HER2 blockade of trastuzumab and pertuzumab plus chemotherapy based on the CLEOPATRA trial.32 This evidence concerns the gene ERBB2 and breast cancer.